Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation
Senti Biosciences stock falls 5% despite receiving FDA RMAT designation for SENTI-202, a promising leukemia treatment. What’s driving the dip.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Senti Biosciences, Inc. (SNTI) Stock: Faces Decline Despite Groundbreaking FDA Designation
Senti Biosciences stock falls 5% despite receiving FDA RMAT designation for SENTI-202, a promising leukemia treatment. What’s driving the dip.